Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Potenciano Paredes

Pediatrics Los Angeles, CA Medical Doctor

NPI 1104856335 CMS profile 185710

1704 W Manchester Ave, Suite 101, Los Angeles, CA 90047

Open in the dashboard

General payments

$2,070

83 records reported · program years 2019–2025

Research payments

$0

Paid to them · None reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Potenciano Paredes of Los Angeles, CA is reported in the CMS Open Payments database as having received $2,070 across 83 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 93rd percentile of Pediatrics profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

7 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $217 10
2024 General $288 8
2023 General $389 19
2022 General $334 10
2021 General $247 12
2020 General $236 11
2019 General $359 13

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Potenciano Paredes
  • Pediatrics median
  • Middle half of Pediatrics
  • National median

In program year 2025, general payments to Potenciano Paredes were reported at $217. Among 22,296 Pediatrics profiles paid that year, the median was $97 and the middle half received between $37 and $210.

Show as a table
Year Potenciano Paredes Pediatrics median Middle half National median
2019 $359 $86 $31–$183 $163
2020 $236 $49 $22–$110 $114
2021 $247 $68 $27–$158 $132
2022 $334 $77 $30–$173 $149
2023 $389 $88 $33–$190 $160
2024 $288 $94 $34–$206 $164
2025 $217 $97 $37–$210 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. GlaxoSmithKline, LLC. $766 27 payments
  2. Pfizer Inc. $442 17 payments
  3. Merck Sharp & Dohme Corporation $289 12 payments
  4. Bayer HealthCare Pharmaceuticals Inc. $128 6 payments
  5. Cranial Technologies, Inc $120 7 payments
  6. Amarin Pharma Inc. $73 3 payments
  7. Sanofi Pasteur Inc. $60 3 payments
  8. Boston Scientific Corporation $55 1 payment
  9. Hologic, LLC $54 2 payments
  10. Kowa Pharmaceuticals America, Inc. $38 2 payments
  11. Other $45 3 payments

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Food and Beverage $2,070 83 payments
Products named General payments · program years 2019–2025
  1. BEXSERO $618 20 payments
  2. EUCRISA $357 13 payments
  3. GARDASIL 9 $231 9 payments
  4. VAXNEUVANCE $182 7 payments
  5. PEDIARIX $161 8 payments
  6. VAXELIS $160 6 payments
  7. ROTATEQ $130 5 payments
  8. Kerendia $128 6 payments
  9. Doc Band $120 7 payments
  10. M-M-R II $108 4 payments
  11. Other $1,233 56 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Records

83 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Pediatrics in California

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record